Podcasts about clinical trials

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if targeting a single cellular pathway could slow aging and boost immunity? Dr. Joan Mannick, a leading voice in aging science, reveals how mTOR inhibitors may be the future of longevity therapeutics. From her early inspiration to groundbreaking clinical trials, Dr. Mannick explores the role of mTOR in aging, immune response, and antiviral immunity. Learn how selective mTOR inhibition could extend healthspan without compromising muscle mass, improve vaccine response in older adults, and unlock new possibilities in clinical longevity. Learn more about Dr. Joan Mannick: https://www.linkedin.com/in/joan-mannick-8089a614/ - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/

In this episode, Mathew Paruthickal — Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi — joins Emerj Editorial Director Matthew DeMello to explore how AI is reshaping clinical trial operations at scale. He shares how Sanofi is leveraging advanced data strategies to address longstanding bottlenecks in trial design, safety signal detection, and site performance prediction. Mathew outlines the architectural and operational shifts required to move from isolated AI pilots to enterprise-wide transformation. From document intelligence to real-time data orchestration, he details how Sanofi is building integrated, compliant systems that support faster, more informed decision-making across teams and therapeutic areas. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

In this episode of Alter Everything, we chat with Patrick Leung, CTO of Faro Health, about the innovative ways his company is using generative AI to revolutionize the clinical trial process. They discuss handling unstructured data, insights generated by AI to optimize trials, and significant cost savings in the pharmaceutical space! Not sure what a clinical trial is? Fear not! Patrick explains the structure of clinical trials, Faro Health's AI-driven enhancements in medical writing, and the importance of data extraction and analysis.Panelists: Patrick Leung, Chief Technical Officer @ Faro Health - LinkedInMegan Bowers, Sr. Content Manager @ Alteryx - @MeganBowers, LinkedInShow notes: Faro HealthAlteryx's Generative AI for AnalyticsClinicaltrials.gov Interested in sharing your feedback with the Alter Everything team? Take our feedback survey here!This episode was produced by Megan Bowers, Mike Cusic, and Matt Rotundo. Special thanks to Andy Uttley for the theme music and Mike Cusic for the for our album artwork.

Vitamin D recommendations in 1941 began this debate. Over the years, updated guidelines have continued to spark controversy and debate in the field of vitamin D research.In this episode of Daily Value, we look at the recent “Vitamin D-ilemma” reinvigorated by the Endocrine Society's updated 2024 guidelines. These new recommendations have dialed back routine testing and supplementation targets, igniting pushback from leading researchers who argue we might be overlooking significant health benefits (including reduced risks for 8 out of the top 10 leading causes of death). Join us as we Look at the evolving science behind vitamin D, why randomized trials and observational studies seem to tell different stories, and how you can practically navigate these conflicting recommendations to optimize your own health.00:00 Introduction: The Vitamin D Controversy01:00 Historical Guidelines and Shifts01:54 The 2011 Guidelines and Their Impact03:57 The 2024 Update: A New Debate06:13 Understanding Vitamin D's Role in the Body07:29 Clinical Trials vs. Observational Studies09:13 Health Benefits of Higher Vitamin D Levels11:58 Challenges in Vitamin D Research15:56 Practical Recommendations for Optimal Vitamin D19:32 Conclusion: Striving for Optimal HealthPMID: 39861407PMID: 38828961PMID: 37004709PMID: 30992519Support the show

Send us a textDoctor Carolyn Tran joins Neurologist Steven Toenjes to discuss migraines. Migraine is a complex brain disease affecting one in five women and one in ten men, with treatments ranging from traditional medications to cutting-edge therapies targeting specific pathways in the brain. The doctors talk about the causes - or lack thereof, the lack of treatment, and common misconceptions about what headaches should be classified as migraines. Dr. Toenjes explains the phases of migraine, including prodrome, aura, pain, and postdrome. Then the two doctors explore many treatment options, discussing the uses, benefits, and drawbacks of each class of treatment.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today is Clinical Trials Awareness Day, making it the perfect time to spotlight a powerful conversation about access, equity, and the future of cancer research. Host Melissa Berry is joined by Dr. Sara Horton, Strategic Clinical Trials Access and Partnerships Lead at Quantum Leap Healthcare to have an insightful and empowering conversation about clinical trials. Dr. Horton is deeply committed to improving access to clinical trials and ensuring diversity in cancer research—an essential step toward creating treatments that truly work for everyone. In this episode, we explore why representation matters in clinical trials, what barriers still exist, and how her work is helping to break them down. We also discuss the groundbreaking Wisdom Study, how to find and join clinical trials, and how they can be a vital part of improving treatment options. Overall, we talk about the importance of clinical trials and why they're so essential—not only to advance research, but also to getting an upgrade to your own care.

How can pediatric and adult urologists team up to tackle complex cancer cases? In this episode of the BackTable Urology, host Dr. Amanda Buchanan, Division Chief of Pediatric Urology at the University of Kentucky, is joined by her colleagues Dr. Patrick Hensley, an adult urologic oncologist, and Dave Rodeberg, Division Chief of Pediatric Surgery. Their discussion centers around the importance of professional collaboration in urologic oncology care in order to improve patient outcomes.---SYNPOSISThe urologists discuss topics such as the experiences and benefits of interdisciplinary collaboration in complex cases and the role of pediatric urologists in treating adolescent and young adult patients. They also provide insights into the Children's Oncology Group (COG) studies and their intersections with adult oncology research. The episode concludes with practical advice for other institutions aiming to improve collaborative efforts between pediatric and adult urology departments.---TIMESTAMPS00:00 - Introduction02:35 - Challenges and Lessons in Multidisciplinary Collaboration08:24 - Pediatric vs. Adult Urologic Oncology11:07- Clinical Trials and Research Collaborations12:49 - Navigating Oncology Groups for Children and Adults19:06 - Collaborative Models in Kidney Cancer Care22:18 - Benefits and Challenges of Collaboration35:24 - Final Thoughts and Recommendations---RESOURCESSociety of Urologic Oncology:https://suonet.org/home.aspxChildren's Oncology Grouphttps://www.childrensoncologygroup.org/

On October 29-30, 2024, the ACCC Community Oncology Research Institute (ACORI) hosted the Community Oncology Inclusive Clinical Trial Design Summit in Arlington, VA. The event brought together stakeholders including academic and community cancer center practitioners and researchers, advocacy organizations, government agencies, and industry partners to discuss strategies to increase patient access to clinical trials in the community setting. Five priority areas were identified that characterize actionable strategies to promote fair and accessible clinical trial design that is representative of all patients with cancer: strengthening the clinical trial workforce, optimizing trial design, engaging communities outside of clinical trial interactions, decentralizing clinical trials, and leveraging artificial intelligence/digital health tools for increased access and efficiency.   ACCC is committed to providing support in these priority areas to increase representative participation and opportunities in clinical trials for oncology patients across the US. In this episode of CANCER BUZZ, Kimberly Demirhan, MBA, BSN, RN, assistant director of education programs at ACCC, discusses the 5 priority areas identified at the ACORI Summit and ways to transform how we think about access to trials, especially leveraging AI and digital tools to do so.   “We looked at optimizing trial design to reflect real world patient populations ... assessing eligibility criteria to make it more reflective of the patient populations that we see out in the community.”   “[We suggest] simplifying protocols so we're not accidentally eliminating patients [due to] benign factors, and then really engaging our community providers early on in the design process.”   “It's a really important time to be addressing [AI] and looking at the opportunities we have to transform the way we think about clinical trials, how we think about the delivery and access to them.” – Kimberly Demirhan   Kimberly Demirhan, MBA, BSN, RN Assistant Director, Education Programs Association of Cancer Care Centers   Resources: 2024 ACORI Summit Just ASK: Increasing Diversity in Cancer Clinical Research Bringing Cancer Research to the Community: Strategic Approaches to Representative Oncology Clinical Trial Design  

On this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today's patients. They dive deeper into the evolution of rare disease patient advocacy groups, why industry must move beyond the hyperfocus on “blockbuster drugs” to make progress in rare disease research, and how advancements in rare disease treatments can benefit the clinical research ecosystem for all.

What if the very tools we rely on to detect breast cancer were putting us at risk? In this eye-opening episode, I sit down with Dr. John Klock, a visionary physician and medical imaging innovator, to expose the truth behind traditional screening methods and reveal a safer, more effective alternative: QT Ultrasound.Dr. Klock shares his incredible journey—from personal diagnosis to pioneering a breakthrough technology that's transforming breast imaging. Together, they unpack the challenges of disrupting an entrenched system, the common misconceptions around FDA clearance vs. approval, and the critical role of metabolic health in breast cancer risk.This episode is packed with life-changing insights about QT technology, the future of screening, and why informed decision-making is every woman's right. If you've ever questioned the safety or necessity of mammography, this conversation is a must-listen.Dr. John Klock is a physician, scientist, and the founder of QT Imaging. With a decades-long career in medical innovation, Dr. Klock is leading the charge to bring safer, radiation-free, high-resolution breast imaging to women across the world. His mission: to change the standard of care in breast health. In This Episode, You Will Learn:Why current imaging methods may be doing more harm than goodHow QT Ultrasound works—and why it's a game changerWhat it means that mammography was never formally FDA-clearedWhy metabolic health is at the center of breast cancer preventionWho qualifies for QT Imaging and how often you actually need to screen✨ This episode is an invitation to reclaim your health with confidence and clarity.If this episode resonated with you, please follow, rate, and leave a review on your favorite podcast platform. And most importantly—share it with a woman you love. This information could change, or even save, her life.

We are joined by Carole Bakhos and Candice Huber this week to talk all things human clinical trials! Candice's family is our first to go through the clinical trial process. We talk all about her experience, what tips you need to know and what's next for all of you. Don't miss out on this crucial […]

Send us a textThe FDA has granted full approval to Novavax's COVID-19 vaccine, providing an alternative to mRNA vaccines that works through a different mechanism using proteins and adjuvants. Despite being four years into the pandemic, COVID-19 remains a significant health concern, causing approximately 1 in 200 deaths in the US in 2025.• Novavax uses bioengineered spike proteins combined with an adjuvant rather than mRNA technology• FDA approved Novavax for all Americans over 65 and those 12-64 with at least one risk factor• Risk factors include conditions like asthma, diabetes, and obesity• Northeast Florida contributed 500 patients to the original Novavax clinical trials• Encore Research Group is currently enrolling participants for an oral COVID vaccine clinical trial• Participants in the oral vaccine trial will receive compensation for their timeFor more information about participating in the oral COVID vaccine study, visit EncoreDocs.com or call 904-730-0101.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textIn this episode of the Life Science Success Podcast my guest is Justin Goodarz, Chief Commercial Officer at Verified Clinical Trials. With extensive experience in strategic partnerships and eClinical technology across leading industry companies, Justin brings a wealth of expertise in enhancing patient recruitment and site centricity to our conversation.00:00 Introduction to Life Science Success Podcast00:45 Meet Justin Goodarz: Chief Commercial Officer at Verified Clinical Trials01:07 Justin's Journey into Life Sciences03:23 Career Highlights and Experiences06:55 Challenges and Innovations at Verified Clinical Trials11:50 Mission and Objectives of Verified Clinical Trials19:56 Leadership Advice and Personal Insights28:22 Conclusion and Final Thoughts

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

This week on the show, we're have our sights set on healthy aging. What would it mean to be able to live to 80, 90 or 100 with our cognitive abilities intact and able to maintain an independent lifestyle right to the end of our days? We're joined by Beth Mormino and Anthony Wagner who lead the Stanford Aging and Memory Study, which recruits cognitively healthy older adults to understand what makes their brains particularly resilient — and how more of us could join them in living the dream of healthy aging.Learn MoreStanford Aging and Memory Study (SAMS)Stanford Memory LabMormino LabFurther ReadingAlzheimer's 'resilience signature' predicts who will develop dementia—and how fast (Knight Initiative for Brain Resilience, 2025)Latest Alzheimer's lab tests focus on memory loss, not brain plaques (NPR, 2025)ReferencesTrelle, A. N., ... & Wagner, A. D. (2020). Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults. eLife, 9:e55335. doi: 10.7554/eLife.55335 PDF | PMID:32469308Trelle, A. N., ..., Wagner, A. D., Mormino, E. C., & Wilson, E. N. (2025). Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. Alzheimer's & Dementia, 21:e14442. PDF | PMID:39713875Sheng, J., ..., Mormino, E., & Wagner, A. D. (submitted). Top-down attention and Alzheimer's pathology impact cortical selectivity during learning, influencing episodic memory in older adults.  PreprintEpisode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with sound design by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute and supported in part by the Knight Iniative for Brain Resilience.Get in touchWe want to hear from your neurons! Email us at at neuronspodcast@stanford.edu if you'd be willing to help out with some listener rSend us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Despite missing the primary endpoint, the treatment improved vision for some patients.

Send us a textDr. Michael Koren shares exciting news about the revival of an oral COVID vaccine study previously halted by government spending cuts. The non-mRNA vaccine trial represents an important alternative approach that apparently received priority status even under strict budget reviews.• Oral COVID vaccine study in Jacksonville now actively enrolling participants after being temporarily halted by DOGE initiative• Study offers a non-mRNA alternative that might appeal to those concerned about messenger RNA technology• Summer months in Florida paradoxically see increases in respiratory infections as people spend more time indoors with air conditioning• Dr. Koren explains why most vaccines require injection rather than oral delivery• Discussion of pharmaceutical pricing disparities between US and other countries• The "innovation premium" Americans pay funds research that benefits the global population• Finding balance between incentivizing medical breakthroughs and ensuring fair cost distribution remains challengingFor reliable, unbiased medical information, visit MedEvidence.com. To learn more about participating in the oral COVID vaccine study or other clinical trials, visit EncoreDocs.com.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textUrologist and president of the Duval County Medical Society Dr. Ali Kasraeian joins Dr. Michael Koren to update us on recent advances in Urology. In Part 3 of this series, Dr. Koren and Dr. Kasraeian dive deep into the latest advancements in prostate cancer detection and treatment options. They explore the evolution from basic PSA screening to personalized approaches . Dr. Kasraeian focuses on the modern shift to patient-focused, individualized approaches that meet patients where they are by balancing early detection with quality of life considerations.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

John Maytham is joined by health policy experts to unpack the US National Institutes of Health’s decision to halt foreign sub-awards — a move that has placed billions of rands in South African HIV and TB research funding at risk. With clinical trials suspended, patient care disrupted, and jobs on the line, this discussion explores the ethical, medical, and geopolitical implications of Washington’s quiet retreat from global health partnerships. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.  Timestamps:     00:00 – Introduction   01:56 – Anti-angiogenic therapies  05:03 – Treatment resistance  07:53 – Genetic polymorphisms  09:02 – Sarcoma treatments  11:16 – Novel drugs  15:22 – Oncology societies  18:00 – Carles' three wishes for healthcare 

In this episode, we explore a new approach to improving participation in lupus clinical trials by strengthening provider outreach and education. Our guest, Dr. Saira Sheikh of UNC Chapel Hill, discusses the TIMELY study, which focuses on involving healthcare providers and community health workers to better connect patients with trial opportunities. From roundtable discussions to changes in provider behavior, we highlight practical strategies that could improve how clinical trials are conducted. 

What trends are shaping the Medtech industry today? In this episode, ⁠Adam Torres⁠ and ⁠Julio Martinez-Clark⁠, CEO at bioaccess®, explore Julio's journey and insights into the state of the Medtech industry. Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠https://missionmatters.lpages.co/podcastguest/⁠ Visit our website: ⁠https://missionmatters.com/⁠ More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

The company is planning a Phase 2/3 clinical trial for therapy in late 2025.

The Informed Consent Form is a participant's first impression of a clinical trial so Lisa Chamberlain James and Ros Cheetham sit down to discuss how to make it the best it can be. Learn about the layout, formatting, crafting tips, where plain language fits in, and its future.  

What does clinical trial monitoring have in common with growing a field of corn? Amy Kroeplin (PPD™ clinical research business of Thermo Fisher Scientific), Shailesh Madel (ICON plc), and Nicole Stansbury (Premier Research) join the podcast to discuss the importance of risk-based quality management, centralized monitoring, and strategic SDV/SDR sampling strategies. They dive deeper into the unique roles of SDV and SDR, different methods of implementing SDV/SDR sampling strategies, and the industry imperative to increase centralized monitoring adoption.

What trends are shaping the Medtech industry today? In this episode, Adam Torres and Julio Martinez-Clark, CEO at bioaccess®, explore Julio's journey and insights into the state of the Medtech industry. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

Part B of the trial will enroll nine adult patients as well as three pediatric patients.

Send us a textDr. Michael Koren shares insights from his recent speaking tour across Saudi Arabia where he delivered 14 lectures in 6 days to sophisticated healthcare providers eager for American medical research. His observations reveal surprising aspects of Saudi healthcare including English as the professional language, universal insurance coverage, and the powerful roles women play despite traditional cultural restrictions.• Saudi Arabia offers universal healthcare coverage with additional private insurance options• English serves as the professional language in Saudi healthcare settings• Women in healthcare occupy positions of authority despite only gaining driving rights in 2019• Female healthcare professionals maintain strong professional presence while following traditional covering practices• Dr. Koren shared research on improving cholesterol management published in JACC• Saudi physicians highly value clinical research conducted in Northeast Florida• The rivalry between Saudi Arabia and Iran remains strong despite geographic proximity• MedEvidence platform received enthusiastic response from Saudi healthcare professionalsVisit MedEvidence.com to learn how we break down complex medical issues, identify knowledge gaps, and explain the research process for both healthcare professionals and patients.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textEffect of kangaroo mother care in low birth weight infants on human milk intake: a randomized controlled trial.Sinha B, Mazumder S, Thakur A, Devi S, More D, Ashorn P, Sommerfelt H, Kurpad A, Bhandari N.Am J Clin Nutr. 2025 May;121(5):1109-1116. doi: 10.1016/j.ajcnut.2025.02.006. Epub 2025 Feb 11.PMID: 39947481 Free article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIntermittent sigh breaths during high-frequency oscillatory ventilation in preterm infants: a randomised crossover study.Hough JL, Jardine L, Hough MJ, Steele M, Greisen G, Heiring C.Arch Dis Child Fetal Neonatal Ed. 2025 Apr 17;110(3):297-302. doi: 10.1136/archdischild-2024-327445.PMID: 39406472 Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Potential Medicaid cuts are looming that could affect our community. Hear how you can take action! We also have exciting news about a clinical trial for von Willebrand's disease and a special community story from Kayla Klein and her mother, Nancy Rodgers. Plus, Patrick has some fantastic updates from the WFH's Comprehensive Care Summit in Dubai.    Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   Medicaid Cuts - Take Action Today!   Please call or email the offices you visited in March and remind your lawmakers that Medicaid is a lifeline: ask them to reject Medicaid funding cuts and other policies that would reduce coverage and disrupt care. For email, contact the staffer you met with at Washington Days (check your sent mail for the thank you notes). If you no longer have contact information for your lawmakers' offices, you can call the Capitol switchboard at 202.224.3121 and ask them to connect you. Say or email:   I am [calling/emailing] as a member of the bleeding disorders community and as a constituent to ask you to reject cuts to federal Medicaid funding. I am relying on you, as my Senator/Representative in Congress, to protect Medicaid from funding cuts and other policies that would reduce coverage and care.    Medicaid covers life-sustaining treatment and care for up to one-third of the bleeding disorders community. Without Medicaid, low-income people with bleeding disorders will have no access to the regular care they need to prevent or treat painful, debilitating, and potentially life-threatening bleeding episodes. People will experience preventable health complications – and overall healthcare costs will rise.   Please stand with the bleeding disorders community and so many others who rely on Medicaid, and reject cuts to this program that provides essential coverage to vulnerable individuals across the country.   ** Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease: Press Release   More information about the vWD clinical trial participation Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter

The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.

Discusses the updated International Council for Harmonisation (ICH) Guideline for Good Clinical Practice known as E6(R3) and what it means for researchers. Our guest today is Cindy Gates, JD, RN, an experienced leader in human subjects research protections and clinical research. Cindy has previously worked at WIRB, the University of California Davis, the University of Miami, the Houston Methodist Medical Center, and George Washington University. This episode is co-hosted by Eric D. Kupferberg, PhD, Associate Director of Clinical Research Education at CITI Program.  Additional resources: ICH E6(R3): https://www.ich.org/page/efficacy-guidelines#6-2 CITI Program's ICH E6(R3): An Introduction course: https://about.citiprogram.org/course/ich-e6r3-an-introduction/ 

We did something BIG! We invested time and a good chunk of change into a clinical trial for my first product ever – seed cycling. Was it worth it? Yes. In this episode, we share all about our clinical study where 40 women embarked on a seed cycling journey for 3 months to see if their symptoms of PMS improved. The results – insane! You'll learn: * How 40 women changed their PMS symptoms in 3 months* Why we invested in a third-party clinical study + all the details* Limitations of the study and nutrition research* The crazy journey that led Yasmin to seed cycling* And more…You can learn more about the first-ever clinical study on seed cycling here: https://beeyawellness.com/pages/clinical-study This episode is brought to you by beeya: * Learn more about beeya's seed cycling bundle at https://beeyawellness.com/free to find out how to tackle hormonal imbalances. * Get $10 off your order by using promo code BEHINDHEREMPIRE10Follow Yasmin: * Instagram: https://www.instagram.com/yasminknouri/* Stay updated & subscribe to our newsletter: https://www.behindherempire.com/Follow Kaya: * Instagram: https://www.instagram.com/kayapurohit/Follow Beeya:* Instagram: https://www.instagram.com/beeyawellness/* Website: https://beeyawellness.com/ Hosted on Acast. See acast.com/privacy for more information.

Today's guest is Damion Nero, Head of Data Science at Takeda Pharmaceuticals. With over 15 years of experience applying AI, machine learning, and real-world data to drug development and precision medicine, Damion joins Emerj Managing Editor Matthew DeMello to explore the evolving role of AI in drug development and supply chain management. He breaks down how AI is currently streamlining administrative and regulatory tasks, improving efficiency across clinical trials, and saving valuable time for healthcare professionals. Damion also discusses why broader, transformative supply chain efficiencies are still on the horizon, as AI continues to evolve and scale in the pharmaceutical industry. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

Send us a textUrologist and president of the Duval County Medical Society Dr. Ali Kasraeian joins Dr. Michael Koren to update us on recent advances in Urology. In Part 2 of this series, Dr. Koren and Dr. Kasraeian explore into the controversial history of PSA testing. Dr. Kasraeian explains how this simple blood test revolutionized prostate cancer detection while creating challenges around overdiagnosis and overtreatment. The doctors also talk about how modern approaches to prostate screening have evolved to balance finding dangerous cancers while avoiding unnecessary interventions.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

On this week's episode, Lisa Moneymaker (SVP, Head of Strategic Customer Engagement, Medidata Solutions) and Adam Aten (Legislative & Regulatory Policy Lead, Verily) join the podcast to discuss how the clinical research industry must use insights from the past to better prepare our AI models and other technologies to meet the needs of patients in the present and future. They dive deeper into the role that collaboration between technologists and clinical scientists can play in helping to reduce bias in our AI models, what legislators and regulators should be keeping top of mind as they write new rules of the road for AI and ML, and ACRO's ongoing efforts to promote the responsible use of AI in clinical research.

As clinical research expands within the optometry field, the research coordinator's role is gaining long-overdue recognition. These professionals make research feasible and compliant in everyday eye care settings. Whether you're an optometrist seeking to diversify your services or a professional exploring a new career path, understanding the function and value of the research coordinator can open doors to innovation and impact.

Jón Ingi Bergsteinsson MedTech founder, former CTO of SMART-TRIAL and now a startup advisor and investor via LIFA Ventures. With 10+ years of hands-on experience scaling a SaaS company in regulated healthcare, Jón offers a rare blend of technical and commercial insight.In this episode, we talk about why founders should stop treating regulatory and commercial teams like separate planets, how VCs really evaluate MedTech startups, and what SaaS-style thinking can teach traditional device companies. Jón also walks us through his “founder-to-fund” journey, shares common pitfalls in clinical trial design and gives a blunt take on why copying pharma's playbook won't work in MedTech.Timestamps:[00:00:35] Why MedTech Startups Still Struggle to Scale[00:03:41] Building SMART-TRIAL Without Venture Capital[00:06:25] Regulatory & Clinical Teams Need to Talk More[00:09:50] LIFA Ventures: Investing Beyond the Spreadsheet[00:12:12] The Hidden Cost of Ignoring Commercialization[00:14:07] Copying Pharma? That's a Mistake[00:17:33] Europe vs U.S. Startup Culture: What Founders Get Wrong[00:20:45] Advice for Early-Stage Founders in Regulated Health[00:24:28] Jón's Life Beyond MedTech: Coaching, Family & Hobbies[00:26:12] One Thing He Wishes Founders Would Stop DoingGet in touch with Jón - https://www.linkedin.com/in/joningib/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

- Trump's Trade Embargo Announcement (0:10) - Impact on Global Trade and BRICS (4:08) - Challenges for U.S. Retailers and Manufacturers (16:32) - China's Strategic Response and Cultural Resilience (16:49) - Geopolitical Implications and Economic Collapse (34:05) - Preparation and Survival Strategies (1:06:23) - Special Reports and Additional Resources (1:14:50) - Mike Adams' Analysis of Geopolitical Factors (1:26:57) - Trump's Strategic Priorities and Western Europe's Reaction (1:30:44) - China's Strategic Advancements and Economic Dominance (1:37:11) - China's Long-Term Strategic Goals and Military Capabilities (1:40:57) - The Petrodollar System and Its Imminent Collapse (1:48:16) - The Rise of the BRICS Nations and the BRICS Blockchain (1:57:51) - Beljanski Foundation's Research and Clinical Trials (2:03:26) - The Importance of Nutritional Milestones and Health Choices (2:23:24) - The Future of Cancer Treatment and Research (2:29:31) - The Role of Technology and Information in Health (2:43:18) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Diseases don't discriminate, so it is crucial that medicines are accessible to and effective for as many people as possible.  In this episode, Sasha Tyndale, Director of Diversity and Patient Inclusion at AbbVie, discusses the company's commitment to inclusive clinical research, highlighting the importance of representing diverse populations affected by diseases. Sasha shares how her team integrates patient perspectives into clinical program design to proactively address potential barriers. She introduces the ADMIRE program, which is focused on engaging underrepresented healthcare professionals in research. Sasha also emphasizes humanizing the healthcare experience by hearing patient stories and addressing challenges. She delves into AbbVie's bold initiatives, including foundational changes to clinical development processes and partnerships with community organizations to increase access to clinical trials and simplify language in study materials. Finally, Sasha challenges listeners to educate themselves and others about clinical research. Tune in and learn how to become an advocate for inclusive healthcare! Resources: Connect with and follow Sasha Tyndale on LinkedIn. Discover more about AbbVie on their LinkedIn and website. Sign up for the ADMIRE program here. If you are considering participating in AbbVie's clinical research program, click here.

HEALTH NEWS   ·                     Health Benefits of Polyphenols from Cherries: A Review of Clinical Trials ·         Three minutes of moderate activity a day may reduce risk of having a cardiovascular event ·                     If You're Over 60, Taking This Fiber Supplement Can Improve Your Brain Health ·         Low iron could cause brain fog during menopause transition, study suggests ·                     Effectiveness of Red Clover for the Treatment of Symptoms in Menopausal Women—A Narrative Review ·         High cannabis use associated with increased colon cancer mortality

You've probably heard of HIIT—but have you heard of “REHIT?” This isn't just another workout trend...it's a new science-backed way to train with maximum efficiency and zero wasted time. If you're still jogging, you're wasting hours for minimal results. In this episode of The Human Upgrade, Dave Asprey sits down with Ulrich Dempfle, German-trained engineer and co-founder of CAROL Bike, to dismantle outdated cardio advice and introduce the 5-minute protocol that's obliterating fitness myths. Forget the treadmill grind. REHIT (Reduced Exertion High-Intensity Training) exercising delivers: • 12% VO₂ max increase• 6x the fitness gains of daily jogging • 62% drop in diabetes risk • 5x more BDNF for brain power —all with just 8 minutes of effort per week. But was it? Ulrich unpacks the hard data, crushes the Zone 2 obsession, and shows how a brand-new way of exercising is giving explosive results—no matter your age or fitness level. What You'll Learn in This Episode: • Why Zone 2 cardio is outdated advice for most people • The science of REHIT and how 2 sprints beat 2-hour workouts • The shocking data on VO₂ max, insulin sensitivity, and lifespan • How CAROL uses AI to personalize exercise for any age or ability • Why most people fail at fitness—and how to fix it • The real role of lactate, BDNF, and HRV in recovery and resilience • How perimenopausal women benefit more from REHIT than HIIT or jogging • Why adherence—not intensity—is the #1 predictor of results • What to do when you're traveling or don't have access to the tech Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • CAROL Bike Website and use code ‘DAVE' for a discount – https://carolbike.com/ • CAROL Bike Instagram - https://www.instagram.com/thecarolbike/?hl=en • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 Introduction to REHIT Training • 00:24 Meet Ulrich Dempfle: The Mind Behind CAROL Bike • 00:51 The Science and Benefits of REHIT • 01:44 Comparing Traditional Cardio to REHIT • 02:32 Dave Asprey's Personal Fitness Journey • 03:43 The Efficiency of REHIT Training • 05:03 Practical Applications and Accessibility of REHIT • 08:22 Addressing Common Concerns and Misconceptions • 11:25 The Future of Fitness: REHIT and Beyond • 18:29 Scientific Validation and Real-World Results • 31:53 Clinical Trials and Tech Integration • 32:06 Upgrade Labs and CAROL Bike • 33:00 Mitochondrial Effectiveness and Insulin Sensitivity • 36:05 Zone Two Training vs. High-Intensity Training • 42:02 REHIT for Perimenopausal Women • 48:18 AI and Personalized Exercise • 57:52 Lactate and Exercise Benefits • 01:01:48 Interval Walking Training • 01:04:01 Conclusion and Future Insights See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

You've probably heard of HIIT—but have you heard of “REHIT?” This isn't just another workout trend...it's a new science-backed way to train with maximum efficiency and zero wasted time. If you're still jogging, you're wasting hours for minimal results. In this episode of The Human Upgrade, Dave Asprey sits down with Ulrich Dempfle, German-trained engineer and co-founder of CAROL Bike, to dismantle outdated cardio advice and introduce the 5-minute protocol that's obliterating fitness myths. Forget the treadmill grind. REHIT (Reduced Exertion High-Intensity Training) exercising delivers: • 12% VO₂ max increase • 6x the fitness gains of daily jogging • 62% drop in diabetes risk • 5x more BDNF for brain power —all with just 8 minutes of effort per week. But what is it? Ulrich unpacks the hard data, crushes the Zone 2 obsession, and shows exactly how a brand-new way of exercising is giving explosive results—no matter your age or fitness level. What You'll Learn in This Episode: • Why Zone 2 cardio is outdated advice for most people • The science of REHIT and how 2 sprints beat 2-hour workouts • The shocking data on VO₂ max, insulin sensitivity, and lifespan • How CAROL uses AI to personalize exercise for any age or ability • Why most people fail at fitness—and how to fix it • The real role of lactate, BDNF, and HRV in recovery and resilience • How perimenopausal women benefit more from REHIT than HIIT or jogging • Why adherence—not intensity—is the #1 predictor of results • What to do when you're traveling or don't have access to the tech Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • CAROL Bike Website and use code ‘DAVE' for a discount – https://carolbike.com/ • CAROL Bike Instagram - https://www.instagram.com/thecarolbike/?hl=en • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 Introduction to REHIT Training • 00:24 Meet Ulrich Dempfle: The Mind Behind CAROL Bike • 00:51 The Science and Benefits of REHIT • 01:44 Comparing Traditional Cardio to REHIT • 02:32 Dave Asprey's Personal Fitness Journey • 03:43 The Efficiency of REHIT Training • 05:03 Practical Applications and Accessibility of REHIT • 08:22 Addressing Common Concerns and Misconceptions • 11:25 The Future of Fitness: REHIT and Beyond • 18:29 Scientific Validation and Real-World Results • 31:53 Clinical Trials and Tech Integration • 32:06 Upgrade Labs and CAROL Bike • 33:00 Mitochondrial Effectiveness and Insulin Sensitivity • 36:05 Zone Two Training vs. High-Intensity Training • 42:02 REHIT for Perimenopausal Women • 48:18 AI and Personalized Exercise • 57:52 Lactate and Exercise Benefits • 01:01:48 Interval Walking Training • 01:04:01 Conclusion and Future Insights See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.